ASH: Blenrep ups survival by 42% in multiple myeloma trial
GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
Health Trends 2025: Reimagining What's Possible
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
Deep Dive: AI 2024
In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and
Maintaining focus to prosper in a complex and rapidly evolvi...
Launching a product is always an intense, pivotal moment, but in a fast moving era of scientific advances and regulatory change, it has become an even more critical enterprise.
Seeking effective, safe treatment for all with precision dos...
Modern medicine moves ever more to precision, personalised medicine, and precision dosing is critical in a world that recognises biological individuality – especially when it comes to paedi
Rare Disease Diagnostics: Advancing Orphan Drug Development ...
This white paper is free and can be downloaded and read at your convenience
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
7th Treg-Directed Therapies Summit
Unravelling Treg Biology, Pioneering Best-in-Class Approaches & Demonstrating Clinical Efficacy to Advance Validated Therapeutic Options in Autoimmunity, Inflammation & Beyond
